Clinical trials testing emactuzumab, which targets colony-stimulating factor receptor 1 (CSF-1R) decreasing the M2 macrophage population, have reportedly improved prognosis of skin cancers patients, like those with melanoma.161,162. This evidence concerns the gene CSF1R and skin neoplasm.